JP2002516273A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002516273A5 JP2002516273A5 JP2000550472A JP2000550472A JP2002516273A5 JP 2002516273 A5 JP2002516273 A5 JP 2002516273A5 JP 2000550472 A JP2000550472 A JP 2000550472A JP 2000550472 A JP2000550472 A JP 2000550472A JP 2002516273 A5 JP2002516273 A5 JP 2002516273A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- pharmaceutical composition
- amide
- clearance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 150000001408 amides Chemical class 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- YDHWWBZFRZWVHO-UHFFFAOYSA-H [oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O YDHWWBZFRZWVHO-UHFFFAOYSA-H 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- UGJCNRLBGKEGEH-UHFFFAOYSA-N sodium-binding benzofuran isophthalate Chemical compound COC1=CC=2C=C(C=3C(=CC(=CC=3)C(O)=O)C(O)=O)OC=2C=C1N(CCOCC1)CCOCCOCCN1C(C(=CC=1C=2)OC)=CC=1OC=2C1=CC=C(C(O)=O)C=C1C(O)=O UGJCNRLBGKEGEH-UHFFFAOYSA-N 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8654398P | 1998-05-22 | 1998-05-22 | |
| US60/086,543 | 1998-05-22 | ||
| PCT/US1999/010948 WO1999061012A2 (en) | 1998-05-22 | 1999-05-19 | Therapeutic dinucleotide and derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002516273A JP2002516273A (ja) | 2002-06-04 |
| JP2002516273A5 true JP2002516273A5 (https=) | 2006-07-13 |
| JP4633927B2 JP4633927B2 (ja) | 2011-02-16 |
Family
ID=22199276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000550472A Expired - Fee Related JP4633927B2 (ja) | 1998-05-22 | 1999-05-19 | 治療用ジヌクレオチドおよび誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6323187B1 (https=) |
| EP (1) | EP1087777B1 (https=) |
| JP (1) | JP4633927B2 (https=) |
| CN (1) | CN1301168A (https=) |
| AT (1) | ATE232733T1 (https=) |
| AU (1) | AU746750B2 (https=) |
| CA (1) | CA2332540A1 (https=) |
| DE (1) | DE69905464T2 (https=) |
| WO (1) | WO1999061012A2 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319908B1 (en) | 1996-07-03 | 2001-11-20 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof |
| US5763447C1 (en) | 1996-07-23 | 2002-05-07 | Inspire Pharmaceuticals | Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds |
| US6596725B2 (en) * | 1997-02-10 | 2003-07-22 | Inspire Pharmaceuticals, Inc. | Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema |
| US7223744B2 (en) * | 1997-02-10 | 2007-05-29 | Inspire Pharmaceuticals, Inc. | Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof |
| US6818629B2 (en) | 1997-02-10 | 2004-11-16 | Inspire Pharmaceuticals, Inc. | Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate |
| US7078391B2 (en) * | 1997-02-10 | 2006-07-18 | Inspire Pharmaceuticals, Inc. | Method of treating edematous retinal disorders |
| US6872710B2 (en) | 1997-07-25 | 2005-03-29 | Inspire Pharmaceuticals, Inc. | Di(uridine 5′)-tetraphosphate and salts thereof |
| US6548658B2 (en) * | 1997-07-25 | 2003-04-15 | Inspire Pharmaceuticals, Inc. | Di-(uridine 5′)-tetraphosphate and salts thereof |
| TW593331B (en) | 1997-07-25 | 2004-06-21 | Inspire Pharmaceuticals Inc | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof |
| KR20010013797A (ko) | 1997-07-25 | 2001-02-26 | 인스파이어 파마슈티컬스 인코퍼레이티드 | 디(우리딘 5'-테트라포스페이트) 염 및 그의 제조방법과용도 |
| US6926911B1 (en) | 1998-12-22 | 2005-08-09 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
| EP2258183A1 (en) * | 1998-12-22 | 2010-12-08 | The University of North Carolina at Chapel Hill | Compounds and uses for the treatment of airway diseases and for the delivery of airway drugs |
| JP4969002B2 (ja) * | 1999-06-08 | 2012-07-04 | ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン | ｒＡＡＶ形質導入を増加するための化合物および方法 |
| WO2001002416A1 (en) * | 1999-06-30 | 2001-01-11 | Yamasa Corporation | Dinucleotide crystals |
| US7241447B1 (en) * | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
| US6864243B1 (en) * | 2000-05-12 | 2005-03-08 | Inspire Pharmaceuticals, Inc. | Method for treating retinal degeneration with purinergic receptor agonists |
| BR0111297A (pt) * | 2000-05-30 | 2004-01-06 | Santen Pharmaceutical Co Ltd | Promotor de migração epitelial corneana |
| US7132408B2 (en) | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US7115585B2 (en) | 2000-08-21 | 2006-10-03 | Inspire Pharmaceuticals, Inc. | Compositions for treating epithelial and retinal tissue diseases |
| US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US6897201B2 (en) * | 2000-08-21 | 2005-05-24 | Inspire Pharmaceuticals, Inc. | Compositions and methods for the treatment of glaucoma or ocular hypertension |
| US7452870B2 (en) | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
| WO2003000056A1 (en) * | 2001-06-25 | 2003-01-03 | Inspire Pharmaceuticals, Inc. | Joint lubrication with p2y purinergic receptor agonists |
| KR20050043761A (ko) | 2001-11-06 | 2005-05-11 | 인스파이어 파마슈티컬스 인코퍼레이티드 | 염증성 질환의 치료 또는 예방 방법 |
| US7084128B2 (en) | 2002-01-18 | 2006-08-01 | Inspire Pharmaceuticals, Inc. | Method for reducing intraocular pressure |
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US7435724B2 (en) | 2002-02-27 | 2008-10-14 | Inspire Pharmaceutical, Inc. | Degradation-resistant mononucleoside phosphate compounds |
| JP2007524379A (ja) * | 2003-03-31 | 2007-08-30 | ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン | 上皮ナトリウムチャンネル関連障害のＰｈａｒｍｉｃｏ−遺伝子治療 |
| US6984628B2 (en) * | 2003-07-15 | 2006-01-10 | Allergan, Inc. | Ophthalmic compositions comprising trefoil factor family peptides |
| US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| US20050131224A1 (en) * | 2003-12-15 | 2005-06-16 | Cti Pet Systems, Inc. | Method for preparing radiolabeled thymidine |
| GB0417886D0 (en) * | 2004-08-11 | 2004-09-15 | Univ Cardiff | Method and means for enhanced pulmonary delivery |
| US7368439B2 (en) * | 2005-06-15 | 2008-05-06 | Bar - Ilan University | Dinucleoside poly(borano)phosphate derivatives and uses thereof |
| US7851456B2 (en) * | 2005-06-29 | 2010-12-14 | Inspire Pharmaceuticals, Inc. | P2Y6 receptor agonists for treating lung diseases |
| EP1941883A1 (en) * | 2007-01-08 | 2008-07-09 | Universität Heidelberg | Use of sodium blockers for an early therapy of obstructive lung diseases |
| CA2749746C (en) * | 2009-01-27 | 2014-08-12 | Teleflex Medical Incorporated | Sputum dissolving suctioning solution for endotracheal and tracheostomy tubes |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| CN108658876A (zh) | 2012-12-17 | 2018-10-16 | 帕里昂科学公司 | 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物 |
| CA2895512C (en) | 2012-12-17 | 2021-10-19 | Parion Sciences, Inc. | Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| CN103923143B (zh) * | 2014-04-10 | 2017-01-11 | 江西科技师范大学 | 一种合成双核苷四磷酸以及p2,p3-（双卤代）亚甲基双核苷四磷酸的方法 |
| WO2017139381A1 (en) | 2016-02-08 | 2017-08-17 | University Of Iowa Research Foundation | Methods to produce chimeric adeno-associated virus/bocavirus parvovirus |
| CA3198936A1 (en) | 2016-03-07 | 2017-09-14 | University Of Iowa Research Foundation | Aav-mediated expression using a synthetic promoter and enhancer |
| US12173305B2 (en) | 2016-05-26 | 2024-12-24 | University Of Iowa Research Foundation | cis and trans requirements for terminal resolution of human bocavirus 1 |
| US11142775B2 (en) | 2017-01-13 | 2021-10-12 | University Of Iowa Research Foundation | Bocaparvovirus small noncoding RNA and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5292498A (en) | 1991-06-19 | 1994-03-08 | The University Of North Carolina At Chapel Hill | Method of treating lung disease with uridine triphosphates |
| US5635160A (en) | 1995-06-07 | 1997-06-03 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions |
| US5900407A (en) * | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
| US5837861A (en) * | 1997-02-10 | 1998-11-17 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency |
| DK0981534T3 (da) * | 1997-02-06 | 2006-09-04 | Inspire Pharmaceuticals Inc | Dinukleotider og deres anvendelser |
| US6060327A (en) * | 1997-05-14 | 2000-05-09 | Keensense, Inc. | Molecular wire injection sensors |
| GB2342176B (en) * | 1998-02-02 | 2001-05-02 | Signature Bioscience Inc | Method and apparatus for detecting molecular binding events |
-
1999
- 1999-05-19 CA CA002332540A patent/CA2332540A1/en not_active Abandoned
- 1999-05-19 AT AT99924313T patent/ATE232733T1/de not_active IP Right Cessation
- 1999-05-19 WO PCT/US1999/010948 patent/WO1999061012A2/en not_active Ceased
- 1999-05-19 JP JP2000550472A patent/JP4633927B2/ja not_active Expired - Fee Related
- 1999-05-19 EP EP99924313A patent/EP1087777B1/en not_active Expired - Lifetime
- 1999-05-19 CN CN99806423A patent/CN1301168A/zh active Pending
- 1999-05-19 DE DE69905464T patent/DE69905464T2/de not_active Expired - Fee Related
- 1999-05-19 AU AU40839/99A patent/AU746750B2/en not_active Ceased
- 1999-05-21 US US09/316,571 patent/US6323187B1/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002516273A5 (https=) | ||
| JP4633927B2 (ja) | 治療用ジヌクレオチドおよび誘導体 | |
| ATE325129T1 (de) | Dinukleotide und ihre verwendungen | |
| JP2002537329A5 (https=) | ||
| JP4399478B2 (ja) | １−（２−（ヒドロキシメチル）−１，３−オキサチオラン−５−イル）−５−フルオロシトシンのｂ型肝炎治療への使用 | |
| JP2009539828A5 (https=) | ||
| BR0015908A (pt) | Emprego de compostos org nicos no tratamento de doenças | |
| JP2020512302A5 (https=) | ||
| JP2002531498A5 (https=) | ||
| JP2002533472A5 (https=) | ||
| JP2013541514A5 (https=) | ||
| JP2002541233A5 (https=) | ||
| JP2008505902A5 (https=) | ||
| JP2005531607A5 (https=) | ||
| JP2010540525A5 (https=) | ||
| JP2002332234A5 (https=) | ||
| BR9610059A (pt) | Método para detectar doença pulmomar | |
| JP2005515978A5 (https=) | ||
| JP2004517049A5 (https=) | ||
| US6555675B2 (en) | Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists | |
| JP2008520662A5 (https=) | ||
| JP2002514623A5 (https=) | ||
| JP2003534318A5 (https=) | ||
| JP2009528259A5 (https=) | ||
| JPS6061536A (ja) | いびき防止剤 |